display
Against the background of the dispute over delayed vaccine deliveries, the Belgian health authority inspected a production facility of the British-Swedish manufacturer AstraZeneca.
As the Belgian Medicines Agency (AFMPS) announced on Thursday, the plant in Seneffe was visited at the request of the EU Commission.
"We are now checking documents and data," said AFMPS spokeswoman Ann Eeckhout of the AFP news agency.
The plant in Seneffe, Belgium is at the center of a dispute between the EU Commission and AstraZeneca over delays in the delivery of corona vaccine to the EU.
AstraZeneca announced last week that it would be able to supply the EU with significantly less vaccine than planned in the near future due to production problems at the plant.
display
An official at the Belgian Ministry of Health said the investigation should show whether the delay was actually due to a production problem at the Belgian site.
A spokesman for the EU Commission announced that the results “will be analyzed with experts from other Member States”.
Brussels is particularly annoyed that Great Britain and other non-EU countries are apparently still to receive unreduced quantities.
AstraZeneca boss Pascal Soriot justified the delays in an interview with the fact that the EU concluded its contract with the company three months later than the UK.
The AstraZeneca vaccine is not yet approved in the EU.
The European Medicines Agency EMA could give the green light for this on Friday.
So far, the vaccines of the Mainz company Biontech and its US partner Pfizer as well as those of the US company Moderna have been approved in the European Union.
All developments on Corona in the live ticker: